DEP irinotecan boosts immuno-oncology in colon cancer models
Filed with ASX · · 6 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- DEP products showcased at AACR 2020
- DEP lutetium effective in human prostate cancer model
- VivaGel BV launched in central and eastern Europe
- DEP irinotecan phase 2 commences after positive phase 1
- SPL7013 shows significant activity against coronavirus
Later from Starpharma
- Starpharma signs new DEP partnership with Chase Sun
- SPL7013 nasal spray for COVID19 development update
- SPL creates slow release soluble DEP remdesivir nanoparticle
- Starpharma awarded $1M MRFF funding for COVID-19 spray
- SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma